IMPATH to list on EASDAQ:
This article was originally published in Clinica
Executive Summary
IMPATH, a source of patient-specific cancer diagnostic and prognostic information, is to list on the Brussels-based EASDAQ stock exchange. The New York-based company has a database with over 475,000 analysed cancer cases. "We believe this listing will raise our commercial profile among important European clinical, medical and healthcare management decision-makers - as well as international investors," said Dr Anu Saad, IMPATH's president and CEO. "A major element of our approach is to form key strategic alliances and to identify partnerships and complementary acquisitions in Europe." The company serves over 4,500 physicians in over 1,740 hospitals and 290 oncology practices.